Patented Pediatric Supplement Brand, Amazon + 45K Pharmacies

$14.2M

Revenue

$4.1M

SDE

5.5x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a pediatric nutritional supplement brand founded roughly 15 years ago by a parent who needed a palatable way to deliver a foul-tasting supplement his pediatrician had prescribed. The product is differentiated in a real way for a consumables business: it holds a granted US patent on its formulation and is the only supplement in its category backed by a randomized controlled trial published in a leading peer-reviewed medical journal. Distribution runs through major national pharmaceutical wholesalers into tens of thousands of pharmacy and hospital locations, with the listing citing roughly 45K pharmacies plus a heavy Amazon presence.

The economics are attractive for an ecommerce operation. On $14.2M of revenue the business throws off $4.15M of SDE (a 29% margin) with a lean team, and roughly 28% of revenue recurs through about 29K active subscribers. Amazon still drives 65% to 70% of sales, but the mix is deliberately shifting toward the higher-margin DTC channel. An email list of nearly 49,000 profiles posting 64% open rates and 4.5-star conversion assets rounds out a genuinely durable customer base.

What makes this notable is the combination of clinical credibility, physician recommendation, patent protection, and multichannel distribution in a category (pediatric health) that parents treat as non-discretionary. The moat is real and the growth levers are almost entirely unpulled: no subscriber-exclusive pricing, no SMS program, unsystematic paid social, US-only Amazon, an untapped international reseller network, and three scoped new product lines. This is less a turnaround and more a well-built asset waiting for capital and operator attention.

Why we like it

Earnings quality is strong for an ecommerce brand: $4.15M SDE on $14.2M revenue is a 29% margin, with roughly 28% of revenue recurring through 29K subscribers. Recurring supplement consumption plus a 49K email list at 64% open rates gives real visibility into repeat demand, not one-time impulse purchases.
The moat is unusually durable for a consumables brand. A granted US patent on the formulation, a published randomized controlled trial in a peer-reviewed journal, and physician recommendation create switching friction and credibility that most Amazon supplement sellers simply cannot replicate. Distribution into tens of thousands of pharmacies and hospitals is a barrier that took years to build.
Market tailwinds favor this product because pediatric health is non-discretionary. Parents do not cut a pediatrician-recommended supplement for their child in a downturn, which insulates the top line from consumer belt-tightening that hammers discretionary DTC brands.
The operator advantage is enormous because the growth levers are documented and untouched. No subscriber-exclusive pricing, no SMS program, no systematic paid social, US-only Amazon, an existing international reseller beachhead, and three scoped new product lines mean a competent operator can compound this without inventing anything new.
The transition risk is well mitigated. A tenured team is willing to stay, a longtime pediatrician Chief Medical Officer will continue, and the retiring seller commits to introductions to physician and wholesaler relationships that are the real engine of distribution.

How to improve it

Launch subscriber-exclusive pricing and a formal loyalty tier immediately. The listing states no subscriber-exclusive pricing exists today, so even a modest incentive should lift the 29K subscriber base and push recurring revenue above the current 28% share, directly improving retention and LTV.
Build the SMS program from zero within the first 90 days. With a 49K email list already posting 64% open rates, layering SMS on top of proven conversion assets is a low-cost, high-ROI channel that captures replenishment revenue this business is currently leaving on the table.
Scale the physician-influencer program the seller flagged as highest-potential and least capital-intensive. Early results are encouraging, so systematize it with tracked referral codes and structured outreach to convert clinical credibility into a repeatable acquisition engine.
Systematically test paid social against the 4.5-star conversion assets. Paid social has never been run methodically, so a disciplined creative and audience testing budget can diversify acquisition away from Amazon dependence and feed the higher-margin DTC channel.
Turn on international expansion using the existing reseller beachhead and by taking the Amazon presence beyond US-only. These channels already have a foothold, so the incremental cost of activation is low relative to the addressable demand abroad.
Accelerate the three already-scoped new product lines to raise average order value and cross-sell into the existing subscriber and email base. Selling more to a proven, high-trust customer base is far cheaper than acquiring new customers and leverages the brand's clinical positioning.
Deliberately shift channel mix toward DTC to expand blended margin. Amazon is 65% to 70% of revenue and declining by design, so reinvesting DTC gains into owned channels reduces platform risk and captures the margin Amazon fees currently absorb.

Diligence notes

Verify the patent status, scope, and remaining life, plus any freedom-to-operate risk. The formulation patent is central to the moat, so confirm it is granted, enforceable, and not nearing expiration, and understand what happens to defensibility when it lapses.
Scrutinize Amazon concentration and account health. With 65% to 70% of revenue on Amazon, review the seller account standing, category ranking stability, review authenticity for the 4.5-star assets, and any history of suspensions or listing hijacking that could threaten the majority of revenue overnight.
Validate the subscriber and recurring revenue claims. Pull cohort-level retention, churn, and reactivation data behind the 29K subscribers and 28% recurring figure, since supplement subscriptions often show high early churn that materially changes LTV assumptions.
Confirm the wholesaler and pharmacy distribution economics. Understand the terms, margins, chargebacks, and reorder cadence across the 45K pharmacy and hospital locations, and whether that channel is genuinely profitable or a low-margin credibility play propped up by Amazon.
Assess regulatory and labeling risk given the pediatric and clinical positioning. Confirm FDA compliance for supplement claims, that the published RCT supports the marketing language used, and that physician-recommendation claims are substantiated to avoid enforcement exposure.
Quantify the SDE normalization and owner add-backs. At a 5.54x multiple on $4.15M SDE, verify the small team is truly sufficient post-sale, that the retiring seller's role is genuinely replaceable by the tenured team, and that no material owner-performed functions are missing from the cost base.

Source

Originally listed on Quiet Light. View original listing →